Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
ACHV
Achieve Life Sciences
$3.15
Login to see Achieve Life Sciences (ACHV) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Chart
$3.12 (+0.96%)
$2.76 (+14.13%)
$2.5 (+26.00%)
$5.08 (-37.99%)
ACHV has Medium Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Price under $5
ACHV overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
ACHV Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ACHV Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayACHV Earnings
The TTM reflects 12-month period, providing review of ACHV financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
What is ACHV current stock price?
What are ACHV stock strengths?
What risks are associated with ACHV stock?
When is ACHV next earnings report?
What is ACHV market cap and volume?
What is ACHV's current Stock IQ?
Should I buy ACHV stock right now?
Is ACHV a Strong Buy right now?
What does a 'Strong Buy' rating mean for ACHV?
What does a 'Strong Sell' rating mean for ACHV?
What factors influence ACHV's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
ACHV
Achieve Life Sciences
Current Price
$3.15
Stock Insights
Strengths
Earnings are forecast to grow
Login to unlock Achieve Life Sciences (ACHV) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$3.12 (+0.96%)
$2.76 (+14.13%)
$2.5 (+26.00%)
$5.08 (-37.99%)
ACHV Analysts Opinion
ACHV Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
ACHV Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ACHV Street view is extremely bullish and have positive views on the near-term outlook
ACHV has Medium Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Price under $5
Average key support and resistance price levels.
Login to displayACHV Earnings
The TTM data reflects the most recent 12-month period, providing overview of ACHV financial performance.
ACHV Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
ACHV Latest Analysis
Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisiniclines Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD. SEATTLE and VANCOUVER British Columbia Sept. 22 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences Inc. (NASDAQ:) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as treatment of nicotine dependence today announced the publication of new data in demonstratin
Mon Sep 22, 2025
ACHV: Preparations Continue as PDUFA Date Assigned. By Achieve Life Sciences Inc. (NASDAQ:ACHV) announced that its new drug application (NDA) for cytisinicline has been accepted by the FDA in a September 3rd press release. Other important developments include the appointment of two internal employees to interim Chief Medical Officer (CMO) and Chief Operations Officer (COO). The promotions reflect a broader change to the executive ranks as the company prepares to transition from a development com
Mon Sep 22, 2025
Achieve Life Sciences strengthens leadership team with new COO.
Thu Sep 18, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ACHV Stock trends
ACHV Stock performance
ACHV Stock analysis
ACHV investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings